95
Participants
Start Date
November 23, 2020
Primary Completion Date
February 27, 2024
Study Completion Date
February 27, 2024
No Intervention
No intervention
donanemab
Administered IV
Abington Neurological Associates, Ltd., Abington
National Clinical Research, Inc, Richmond
Guilford Neurologic Research, PA, Greensboro
Progressive Medical Research, Port Orange
Synexus Clinical Research US, Inc., Orlando
Merritt Island Medical Research, LLC, Merritt Island
Advanced Research Consultants, Palm Beach Gardens
Stedman Clinical Trials, Tampa
Bradenton Research Center, Inc., Bradenton
Intercoastal Medical Group - Hyde Park, Sarasota
Ohio State University, Columbus
Neurology Diagnostics, Inc., Dayton
Indiana University, Indianapolis
Josephson Wallack Munshower Neurology, PC, Indianapolis
Washington University, St Louis
The University of Kansas - Clinical Research Center, Fairway
Cotton O'Neil Clinical Research Center - Central Office, Topeka
Banner Alzheimer's Institute, Phoenix
Las Vegas Medical Research, Las Vegas
UC Irvine-Institute for Memory Impairments and Neurological Disorders (UCI MIND), Irvine
Boston Center for Memory, Newton
Advanced Memory Research Institute of New Jersey, Toms River
Rhode Island Hospital, Providence
Bruyère Research Institute, Ottawa
Toronto Memory Program, Toronto
Clinique de la Mémoire de l'Outaouais, Gatineau
Diex Recherche Sherbrooke Inc., Sherbrooke
Eli Lilly and Company
INDUSTRY